These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

233 related items for PubMed ID: 19826134

  • 1. Long-term evaluation of Ifosfamide-related nephrotoxicity in children.
    Oberlin O, Fawaz O, Rey A, Niaudet P, Ridola V, Orbach D, Bergeron C, Defachelles AS, Gentet JC, Schmitt C, Rubie H, Munzer M, Plantaz D, Deville A, Minard V, Corradini N, Leverger G, de Vathaire F.
    J Clin Oncol; 2009 Nov 10; 27(32):5350-5. PubMed ID: 19826134
    [Abstract] [Full Text] [Related]

  • 2. Ifosfamide-induced nephrotoxicity in 593 sarcoma patients: a report from the Late Effects Surveillance System.
    Stöhr W, Paulides M, Bielack S, Jürgens H, Treuner J, Rossi R, Langer T, Beck JD.
    Pediatr Blood Cancer; 2007 Apr 10; 48(4):447-52. PubMed ID: 16628552
    [Abstract] [Full Text] [Related]

  • 3. Risk factors for long-term outcome of ifosfamide-induced nephrotoxicity in children.
    Loebstein R, Atanackovic G, Bishai R, Wolpin J, Khattak S, Hashemi G, Gobrial M, Baruchel S, Ito S, Koren G.
    J Clin Pharmacol; 1999 May 10; 39(5):454-61. PubMed ID: 10234592
    [Abstract] [Full Text] [Related]

  • 4. Risk factors for nephrotoxicity after ifosfamide treatment in children: a UKCCSG Late Effects Group study. United Kingdom Children's Cancer Study Group.
    Skinner R, Cotterill SJ, Stevens MC.
    Br J Cancer; 2000 May 10; 82(10):1636-45. PubMed ID: 10817497
    [Abstract] [Full Text] [Related]

  • 5. Renal dysfunctions secondary to ifosfamide treatment in children.
    Tokuc G, Yalçiner A, Kebudi R, Dogan S, Görgün O, Ayan I.
    J Exp Clin Cancer Res; 1997 Jun 10; 16(2):227-30. PubMed ID: 9261752
    [Abstract] [Full Text] [Related]

  • 6. Glomerular toxicity persists 10 years after ifosfamide treatment in childhood and is not predictable by age or dose.
    Skinner R, Parry A, Price L, Cole M, Craft AW, Pearson AD.
    Pediatr Blood Cancer; 2010 Jul 01; 54(7):983-9. PubMed ID: 20405516
    [Abstract] [Full Text] [Related]

  • 7. Growth impairment after ifosfamide-induced nephrotoxicity in children.
    Stöhr W, Patzer L, Paulides M, Kremers A, Beck JD, Langer T, Rossi R.
    Pediatr Blood Cancer; 2007 May 01; 48(5):571-6. PubMed ID: 16755549
    [Abstract] [Full Text] [Related]

  • 8. Renal toxicity of ifosfamide in pilot regimens of the intergroup rhabdomyosarcoma study for patients with gross residual tumor.
    Raney B, Ensign LG, Foreman J, Khan F, Newton W, Ortega J, Ragab A, Wharam M, Wiener E, Maurer H.
    Am J Pediatr Hematol Oncol; 1994 Nov 01; 16(4):286-95. PubMed ID: 7978043
    [Abstract] [Full Text] [Related]

  • 9. Ifosfamide nephropathy in patients with sarcoma.
    Mashhadi MA, Sanadgol H, Keikhaei M.
    Iran J Kidney Dis; 2011 Jul 01; 5(4):238-41. PubMed ID: 21725180
    [Abstract] [Full Text] [Related]

  • 10. A Southwest Oncology Group and Cancer and Leukemia Group B phase II study of doxorubicin, dacarbazine, ifosfamide, and mesna in adults with advanced osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma.
    Antman K, Crowley J, Balcerzak SP, Kempf RA, Weiss RB, Clamon GH, Baker LH.
    Cancer; 1998 Apr 01; 82(7):1288-95. PubMed ID: 9529020
    [Abstract] [Full Text] [Related]

  • 11. Nephrotoxicity of cisplatin and carboplatin in sarcoma patients: a report from the late effects surveillance system.
    Stöhr W, Paulides M, Bielack S, Jürgens H, Koscielniak E, Rossi R, Langer T, Beck JD.
    Pediatr Blood Cancer; 2007 Feb 01; 48(2):140-7. PubMed ID: 16724313
    [Abstract] [Full Text] [Related]

  • 12. Persistent nephrotoxicity during 10-year follow-up after cisplatin or carboplatin treatment in childhood: relevance of age and dose as risk factors.
    Skinner R, Parry A, Price L, Cole M, Craft AW, Pearson AD.
    Eur J Cancer; 2009 Dec 01; 45(18):3213-9. PubMed ID: 19850470
    [Abstract] [Full Text] [Related]

  • 13. [A prospective study on nephrotoxicity induced by continuous infusion of high-dose ifosfamide (15/m2)].
    Ferrari S, Zolezzi C, Bacci G, Pieretti F, Iantorno D, Figus E, Pizzoferrato A.
    Minerva Pediatr; 1997 Dec 01; 49(1-2):29-37. PubMed ID: 9132558
    [Abstract] [Full Text] [Related]

  • 14. Ifosfamide in the treatment of pediatric malignancies.
    Voûte PA, van den Berg H, Behrendt H, Michiels E, de Kraker J.
    Semin Oncol; 1996 Jun 01; 23(3 Suppl 7):8-11. PubMed ID: 8711502
    [Abstract] [Full Text] [Related]

  • 15. [Ifosfamide in pediatric malignancy--experiences in the Northern Israel Oncology Center].
    Roguin A, Ben Arush MW, Higasi A, Kuten A.
    Harefuah; 1996 Apr 15; 130(8):511-4, 584. PubMed ID: 8765870
    [Abstract] [Full Text] [Related]

  • 16. Chronic ifosfamide nephrotoxicity in children.
    Skinner R.
    Med Pediatr Oncol; 2003 Sep 15; 41(3):190-7. PubMed ID: 12868118
    [Abstract] [Full Text] [Related]

  • 17. Testicular function of survivors of childhood cancer: a comparative study between ifosfamide- and cyclophosphamide-based regimens.
    Ridola V, Fawaz O, Aubier F, Bergeron C, de Vathaire F, Pichon F, Orbach D, Gentet JC, Schmitt C, Dufour C, Oberlin O.
    Eur J Cancer; 2009 Mar 15; 45(5):814-8. PubMed ID: 19216070
    [Abstract] [Full Text] [Related]

  • 18. Safety and efficacy of adjuvant single-agent ifosfamide in uterine sarcoma.
    Kushner DM, Webster KD, Belinson JL, Rybicki LA, Kennedy AW, Markman M.
    Gynecol Oncol; 2000 Aug 15; 78(2):221-7. PubMed ID: 10926807
    [Abstract] [Full Text] [Related]

  • 19. Progressive glomerular toxicity of ifosfamide in children.
    Prasad VK, Lewis IJ, Aparicio SR, Heney D, Hale JP, Bailey CC, Kinsey SE.
    Med Pediatr Oncol; 1996 Sep 15; 27(3):149-55. PubMed ID: 8699991
    [Abstract] [Full Text] [Related]

  • 20. [Continuous-infusion high dose ifosfamide as salvage treatment for pre-treated soft tissue sarcoma].
    Chen LK, Xu GC, Teng XY, Liang Y, Liu JL, Zhou XM.
    Ai Zheng; 2002 Aug 15; 21(8):903-6. PubMed ID: 12478904
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.